Astrana Health, Inc. P/E Ratio 2011–2025
Astrana Health, Inc. reported 53.93 of price-to-earnings ratio for fiscal 2025. That was 54.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +198.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 53.93 | +54.0% |
| FY 2024 | 35.03 | +18.0% |
| FY 2023 | 29.69 | -0.7% |
| FY 2022 | 29.89 | -38.2% |
| FY 2021 | 48.34 | +167.2% |
| FY 2020 | 18.09 | -61.7% |
| FY 2019 | 47.21 | -31.0% |
| FY 2018 | 68.45 | +156.7% |
| FY 2017 | 26.67 | — |
| FY 2017 | — | — |
| FY 2016 | 18.29 | — |
| FY 2016 | — | — |
| FY 2015 | — | — |
| FY 2014 | — | — |
| FY 2013 | — | — |
| FY 2012 | — | — |
| FY 2011 | — | — |
Source: Astrana Health, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open ASTH 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Astrana Health, Inc. reported 53.93 of price-to-earnings ratio for fiscal 2025. That was 54.0% higher than fiscal 2024. Compared with fiscal 2020, the change was +198.2%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Astrana Health, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeAstrana Health, Inc. — frequently asked questions
What is Astrana Health, Inc.'s price-to-earnings ratio?
Astrana Health, Inc. (ASTH) reported price-to-earnings ratio of 53.93 for fiscal year 2025, per its SEC filings.
How has Astrana Health, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2011 and 2025, ASTH's price-to-earnings ratio grew at roughly 8.0% per year (compound annual rate), from 18.29 to 53.93.
Where does this data come from?
Figures are computed from Astrana Health, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More ASTH financial history
Full ASTH fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →